SAICoDis – Safety of Argatroban Infusion in Conduction Disturbances. A prospective, open, monocentric safety study to investigate conduction disturbances in patients receiving argatroban therapy.
Phase of Trial: Phase IV
Latest Information Update: 24 Jan 2019
Price : $35 *
At a glance
- Drugs Argatroban (Primary)
- Indications Coronary arteriosclerosis
- Focus Therapeutic Use
- Acronyms SAICoDis
- Sponsors Mitsubishi Tanabe Pharma GmbH
- 19 Jan 2019 Status changed from suspended to recruiting.
- 03 Jul 2018 Status changed from recruiting to suspended.
- 24 Aug 2017 Planned End Date changed from 9 Jun 2017 to 9 Nov 2017.